2022
A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy
Ibrahim EY, Munshani S, Domenicano I, Rodwin R, Nowak RJ, Pusztai L, Lustberg M, Ehrlich BE. A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy. PLOS ONE 2022, 17: e0275648. PMID: 36206298, PMCID: PMC9543876, DOI: 10.1371/journal.pone.0275648.Peer-Reviewed Original ResearchConceptsNeurological side effectsSide effectsBreast cancerTaxane exposureProgressive neurological changesTaxane-based chemotherapyNon-interventional studyWeeks of treatmentEnd of treatmentIrreversible side effectsCourse of treatmentQuality of lifeTaxane therapyPeripheral neuropathyProspective studyPeripheral bloodBlood levelsCancer survivalNeuronal viabilityNeurological changesEffective treatmentChemotherapyCognitive impairmentPatientsPotential protein biomarkers
2019
Personalizing Treatment Selection for Breast Cancer
Pusztai L, Yeoh C. Personalizing Treatment Selection for Breast Cancer. 2019, 297-324. DOI: 10.1201/9780429066504-14.Peer-Reviewed Original ResearchBreast cancerTreatment selectionClinical outcomesRisk of recurrenceMultiple treatment optionsParticular clinical outcomesCurrent treatment modalitiesCancer-related deathMore effective treatmentsProbability of benefitBreast cancer researchUnited States FoodSurgical resectionProbability of responseTrastuzumab therapyCommon malignancyTreatment optionsClinicopathologic variablesPatient preferencesSpecific therapyTreatment modalitiesMulti-gene testsDisease outcomeMolecular differencesEffective treatment